AVBP
ArriVent BioPharma Inc.

96
Mkt Cap
$830.58M
Volume
620,589.00
52W High
$29.71
52W Low
$15.47
PE Ratio
-4.75
AVBP Fundamentals
Price
$20.12
Prev Close
$20.72
Open
$20.60
50D MA
$21.05
Beta
0.95
Avg. Volume
317,942.53
EPS (Annual)
-$2.39
P/B
2.69
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2% - What's Next?
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2% - Time to Sell...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat.com...
MarketBeat·13d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 5.6% - Time to Sell...
MarketBeat·14d ago
News Placeholder
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B PR Newswire VANCOUVER, BC, Dec. 16, 2025 Issued on...
PR Newswire·16d ago
News Placeholder
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP
Fund 1 Investments LLC bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·18d ago
News Placeholder
BTIG Research Upgrades ArriVent BioPharma (NASDAQ:AVBP) to "Strong-Buy"
BTIG Research upgraded shares of ArriVent BioPharma to a "strong-buy" rating in a report on Wednesday...
MarketBeat·21d ago
News Placeholder
HC Wainwright Has Negative Estimate for AVBP FY2025 Earnings
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on Tuesday...
MarketBeat·2mo ago
News Placeholder
What is Lifesci Capital's Estimate for AVBP FY2025 Earnings?
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Investment analysts at Lifesci Capital cut their FY2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on...
MarketBeat·2mo ago
News Placeholder
Citigroup Cuts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $31.00
Citigroup decreased their price target on shares of ArriVent BioPharma from $33.00 to $31.00 and set a "buy" rating for the company in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·2mo ago
<
1
2
...
>

Latest AVBP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.